ERGO

Entia Biosciences (PK) Stock Price

0.045
-0.035 (-43.75%)
0.045

Low
0.0074

52 Week Range

High
0.3899

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Entia Biosciences Inc (PK) ERGO OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.035 -43.75% 0.045 15:19:02
Open Price Low Price High Price Close Price Prev Close
0.026 0.026 0.045 0.045 0.08
Bid Price Ask Price Spread News
0.028 0.045 0.017 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13 225,402 $ 0.02948 $ 6,645 - 0.0074 - 0.3899
Last Trade Time Type Quantity Stock Price Currency
15:19:02 25,000 $ 0.045 USD

Period:

Draw Mode:

Entia Biosciences Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.53M 34.06M 11.52M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
31.29k $ - - - -

more financials information »

Entia Biosciences (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ERGO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0610.090.0260.0789526119,014-0.016-26.23%
1 Month0.06250.0990.0260.0756562101,236-0.0175-28.0%
3 Months0.138160.1990.0260.1136822172,604-0.09316-67.43%
6 Months0.025130.38990.0135750.1102239166,2150.0198779.07%
1 Year0.0150.38990.00740.1010802110,8240.03200.0%
3 Years0.010.38990.00610.079124974,3420.035350.0%
5 Years0.0450.38990.0050.06802352,5790.000.0%

Entia Biosciences (PK) Description

Entia develops patented, pharmaceutical-grade organic compounds, including one known as ErgoD2. Entia believes that ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entia's goal is to clinically validate and commercialize ErgoD2 through the prescription Medical Food and OTC Supplement channels.


Your Recent History
USOTC
ERGO
Entia Bios..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.